Structure-Activity Relationship of 4,6-Disubstituted Pyrimidines as EGFR and VEGFR-2 Tyrosine Kinase Inhibitors

被引：2
|
作者：
Song, Jiho [1 ]
Lee, Jung Wook [1 ]
Chung, Shin Hyuck [1 ]
Wenas, Michelle A. [1 ]
Min, Kyung Hoon [1 ]
机构：
[1] Chung Ang Univ, Coll Pharm, Seoul 06974, South Korea
来源：
BULLETIN OF THE KOREAN CHEMICAL SOCIETY | 2017年 / 38卷 / 11期
基金：
新加坡国家研究基金会;
关键词：
EGFR; VEGFR-2; Tyrosine kinase inhibitors; Pyrimidine; GROWTH-FACTOR RECEPTOR; BEVACIZUMAB; ERLOTINIB; CANCER; RESISTANCE; THERAPY; CELL;
D O I：
10.1002/bkcs.11278
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
[No abstract available]
引用
收藏
页码：1255 / 1256
页数：2
相关论文
共 50 条
  • [31] Synthesis and Structure-Activity Relationship of 2,6-Disubstituted Thiosemicarbazone Derivatives of Pyridine as Potential Antituberculosis Agents
    Ziembicka, Dagmara
    Gobis, Katarzyna
    Szczesio, Malgorzata
    Olczak, Andrzej
    Augustynowicz-Kopec, Ewa
    Glogowska, Agnieszka
    Korona-Glowniak, Izabela
    Bojanowski, Krzysztof
    MATERIALS, 2023, 16 (01)
  • [32] Structure-activity relationship studies of sphingosine kinase inhibitors
    Raje, Mithun R.
    Kharel, Yugesh
    Lynch, Kevin R.
    Santos, Webster L.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [33] Structure-Activity Relationship in the Leucettine Family of Kinase Inhibitors
    Tahtouh, Tania
    Durieu, Emilie
    Villiers, Benoit
    Bruyere, Celine
    Thu Lan Nguyen
    Fant, Xavier
    Ahn, Kwang H.
    Khurana, Leepakshi
    Deau, Emmanuel
    Lindberg, Mattias F.
    Severe, Elodie
    Miege, Frederic
    Roche, Didier
    Limanton, Emmanuelle
    L'helgoual'ch, Jean-Martial
    Burgy, Guillaume
    Guiheneuf, Solene
    Herault, Yann
    Kendall, Debra A.
    Carreaux, Francois
    Bazureau, Jean-Pierre
    Meijer, Laurent
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (02) : 1396 - 1417
  • [34] Design, synthesis and anticancer activity of benzofuran derivatives targeting VEGFR-2 tyrosine kinase
    Abdelhafez, Omaima M.
    Amin, Kamelia M.
    Ali, Hamed I.
    Abdalla, Mohamed M.
    Ahmed, Eman Y.
    RSC ADVANCES, 2014, 4 (23) : 11569 - 11579
  • [35] Inhibitors of Src tyrosine kinase: The preparation and structure-activity relationship of 4-anilino-3-cyanoquinolines and 4-anilinoquinazolines
    Wang, YD
    Miller, K
    Boschelli, DH
    Ye, F
    Wu, BQ
    Floyd, MB
    Powell, DW
    Wissner, A
    Weber, JM
    Boschelli, F
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (21) : 2477 - 2480
  • [36] Structure-activity relationship of 7-aryl-2-anilino-pyrrolopyrimidines as Mer and Axl tyrosine kinase inhibitors
    Chung, Shin Hyuck
    Park, Jiwon
    Lee, Jung Wuk
    Song, Jiho
    Jung, Danbee
    Min, Kyung Hoon
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2020, 35 (01) : 1822 - 1833
  • [37] Discovery of novel Benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors
    Hasegawa, Masaichi
    Nishigaki, Naohiko
    Washio, Yoshiaki
    Kano, Kazuya
    Harris, Philip A.
    Sato, Hideyuki
    Mori, Ichiro
    West, Rob I.
    Shibahara, Megumi
    Toyoda, Hiroko
    Wang, Liping
    Nolte, Robert T.
    Veal, James M.
    Cheung, Mui
    JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (18) : 4453 - 4470
  • [38] Development and in vivo evaluation of novel inhibitors of the VEGF receptor tyrosine kinase KDR (VEGFR-2)
    Bilodeau, MT
    Coll, KE
    Cunningham, AM
    Hartman, GD
    Huckle, WR
    Hungate, RW
    Kendall, RL
    Koester, TJ
    Rodman, LD
    McFall, RC
    Mao, XZ
    Rutledge, RE
    Thomas, KA
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 223 : B142 - B142
  • [39] Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors
    Hennequin, LF
    Thomas, AP
    Johnstone, C
    Stokes, ESE
    Plé, PA
    Lohmann, JJM
    Ogilvie, DJ
    Dukes, M
    Wedge, SR
    Curwen, JO
    Kendrew, J
    Lambert-van der Brempt, C
    JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (26) : 5369 - 5389
  • [40] Structure-activity relationship of C4-substituted pyrimidopyrimidines; Dual KDR/FGFR tyrosine kinase inhibitors.
    Rossman, P
    Luk, K
    Chen, Y
    Garafalo, L
    Graves, B
    Jackson, N
    Kabat, M
    Konzelmann, F
    Liu, JJ
    Lukacs, C
    McDermott, L
    Michoud, C
    Portland, L
    Roberts, J
    Schutt, A
    Simcox, M
    So, SS
    Tamborini, B
    Yang, H
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U129 - U129
12345